ReviewFrontiers in aging2025
Strength training and sarcopenia-a mandatory link: focus on MicroRNAs.
Review in Frontiers in aging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Sarcopenia in breast cancer: prognostic values and emerging therapeutic strategies.Frontiers in surgery · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the last 20 years, increased life expectancy has been observed in men and women, resulting in a rise in the prevalence of diseases among the aging population. From this, sarcopenia has an estimated prevalence of 10%-16% of older people worldwide. Losing strength and muscle mass in the 65-70 age group represents a significant public health problem. In this review, we emphasize the essential importance of strength training in managing sarcopenia, highlighting the role of microRNAs, small nucleotides that were the subject of last year's Nobel Prize in Physiology or Medicine. These microRNAs regulate protein synthesis and are present in all biological fluids. Some of them are expressed differently by subjects affected by sarcopenia (as happens in various forms of cancer or other diseases). Therefore, monitoring a specific signature of microRNAs can better clarify the etiopathology of sarcopenia, providing an early biomarker for sarcopenia (currently, there are some hypotheses, but none is well recognized), and even serve as the basis for the development of drugs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.